Profile data is unavailable for this security.
About the company
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
- Revenue in SEK (TTM)226.50m
- Net income in SEK-332.86m
- Incorporated1997
- Employees109.00
- LocationBioInvent International ABThe Gamma Building, Ideongatan 1LUND 223 70SwedenSWE
- Phone+46 462868550
- Fax+46 462110806
- Websitehttps://www.bioinvent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medivir AB | 8.50m | -94.40m | 719.53m | 10.00 | -- | 2.24 | -- | 84.65 | -0.6372 | -0.6372 | 0.0596 | 0.5895 | 0.0355 | -- | 1.97 | 850,000.00 | -39.42 | -35.87 | -47.59 | -42.96 | -- | -- | -1,110.59 | -925.95 | -- | -51.44 | -- | -- | 143.97 | -9.43 | 23.45 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -57.59m | 762.97m | 7.00 | -- | 26.49 | -- | -- | -0.3183 | -0.3183 | 0.00 | 0.2091 | 0.00 | -- | -- | 0.00 | -97.85 | -78.53 | -109.76 | -91.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.70 | -- | -- | -- |
| Nykode Therapeutics ASA | 0.00 | -113.24m | 948.95m | 59.00 | -- | 1.12 | -- | -- | -0.3619 | -0.3619 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -9.66 | -13.65 | -10.28 | -15.31 | -- | -- | -- | -220.65 | -- | -- | 0.0271 | -- | -100.00 | -- | 68.47 | -- | -17.43 | -- |
| Xspray Pharma publ AB | 0.00 | -171.45m | 1.01bn | 26.00 | -- | 1.68 | -- | -- | -4.44 | -4.44 | 0.00 | 14.49 | 0.00 | -- | -- | 0.00 | -21.90 | -25.02 | -24.53 | -27.10 | -- | -- | -- | -- | 7.41 | -10.72 | 0.1971 | -- | -- | -- | 39.95 | -- | -20.78 | -- |
| Cantargia AB | 316.70m | 146.98m | 1.07bn | 22.00 | 7.27 | 4.02 | 7.12 | 3.38 | 0.5912 | 0.5912 | 1.27 | 1.07 | 1.36 | -- | 4.89 | 14,395,550.00 | 62.93 | -49.66 | 76.73 | -57.73 | -- | -- | 46.41 | -326.18 | -- | 21.62 | -- | -- | -- | -- | 190.92 | -- | -44.55 | -- |
| Curasight A/S | -71.54m | -76.66m | 1.13bn | 4.00 | -- | 45.56 | -- | -- | -1.11 | -1.11 | -1.13 | 0.3743 | -1.35 | -- | -- | -- | -144.37 | -56.78 | -415.10 | -68.71 | -- | -- | -- | -- | -- | -17.72 | 0.5828 | -- | -51.77 | -- | -44.51 | -- | -- | -- |
| Nightingale Health Oyj | 50.51m | -198.69m | 1.32bn | 100.00 | -- | 1.32 | -- | 26.23 | -0.3052 | -0.3052 | 0.0778 | 1.10 | 0.0568 | 0.9444 | 2.79 | 46,930.00 | -22.33 | -15.66 | -24.26 | -16.95 | 75.39 | 75.21 | -393.39 | -447.17 | 8.52 | -- | 0.0511 | -- | 7.69 | 21.38 | -5.71 | -- | -12.69 | -- |
| Solar Foods Oyj | 1.33m | -123.96m | 1.35bn | 56.00 | -- | 9.01 | -- | 1,014.34 | -0.4666 | -0.4666 | 0.005 | 0.4654 | 0.0032 | -- | 0.0153 | 2,206.96 | -29.50 | -- | -35.51 | -- | 3,682.88 | -- | -9,319.20 | -- | -- | -9.31 | 0.5944 | -- | 560.26 | -- | -4.50 | -- | -- | -- |
| Thor Medical ASA | 479.05k | -55.57m | 1.41bn | 13.00 | -- | 3.24 | -- | 2,953.00 | -0.1803 | -0.1803 | 0.0015 | 1.29 | 0.0009 | -- | 0.0444 | -- | -10.35 | -32.89 | -11.00 | -40.41 | -- | -- | -11,620.00 | -136,767.80 | 4.50 | -- | 0.2732 | -- | -- | -- | -37.41 | -- | 230.64 | -- |
| BioInvent International AB | 226.50m | -332.86m | 1.42bn | 109.00 | -- | 2.55 | -- | 6.28 | -5.05 | -5.05 | 3.44 | 8.47 | 0.2728 | -- | 11.07 | 2,077,936.00 | -40.09 | -22.49 | -45.82 | -24.02 | -- | -- | -146.96 | -205.40 | 5.56 | -- | 0.0151 | -- | 406.86 | 8.98 | 22.48 | -- | 1.62 | -- |
| Devyser Diagnostics AB | 250.60m | -8.40m | 1.46bn | 116.00 | -- | 4.11 | 81.41 | 5.81 | -0.5142 | -0.5142 | 15.09 | 21.27 | 0.5312 | 1.45 | 4.65 | 2,160,345.00 | -1.95 | -8.59 | -2.30 | -9.76 | 80.61 | 81.08 | -3.67 | -22.20 | 2.36 | 0.6429 | 0.1278 | -- | 15.49 | 30.70 | 86.34 | -- | 83.06 | -- |
| Cereno Scientific AB | 0.00 | -113.30m | 1.81bn | 5.00 | -- | 8.83 | -- | -- | -0.3987 | -0.3987 | 0.00 | 0.6572 | 0.00 | -- | -- | -- | -30.72 | -20.10 | -32.58 | -21.72 | -- | -- | -- | -- | -- | -1.94 | 0.4817 | -- | -- | -- | -106.89 | -- | 47.93 | -- |
| Egetis Therapeutics AB (publ) | 62.50m | -342.60m | 1.88bn | 40.00 | -- | 5.54 | -- | 30.03 | -0.9237 | -0.9237 | 0.1698 | 0.8571 | 0.0873 | 30.36 | 3.60 | 1,562,500.00 | -47.87 | -39.01 | -69.47 | -46.68 | 19.84 | 61.77 | -548.16 | -577.70 | 1.04 | -35.79 | 0.1951 | -- | 35.36 | 8.94 | 0.3201 | -- | 128.65 | -- |
| Diamyd Medical AB | 348.00k | -182.46m | 1.91bn | 41.00 | -- | 8.44 | -- | 5,475.38 | -1.52 | -1.52 | 0.0029 | 1.68 | 0.0013 | -- | 18.81 | 8,923.08 | -69.46 | -44.47 | -76.54 | -49.74 | -- | -- | -52,430.46 | -31,802.45 | -- | -- | 0.1628 | -- | 0.00 | -17.54 | -11.81 | -- | 38.40 | -- |
| Saniona AB | 434.40m | 284.67m | 2.07bn | 34.00 | 7.21 | 3.26 | 7.11 | 4.77 | 2.08 | 2.08 | 3.32 | 4.60 | 0.8522 | -- | 44.79 | 12,776,440.00 | 55.85 | -14.54 | 65.47 | -17.31 | 78.84 | 27.41 | 65.53 | -30.17 | -- | -- | 0.00 | -- | 29.80 | 121.23 | 50.85 | -- | 71.22 | -- |
Data as of Mar 04 2026. Currency figures normalised to BioInvent International AB's reporting currency: Swedish Krona SEK
34.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Dec 2024 | 10.02m | 15.23% |
| HBM Partners AG (Investment Management)as of 31 Dec 2024 | 5.08m | 7.71% |
| Fj�rde AP-fondenas of 31 Dec 2024 | 4.02m | 6.11% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 1.32m | 2.00% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 30 Nov 2025 | 742.90k | 1.13% |
| Atle Fund Management ABas of 31 Dec 2024 | 475.75k | 0.72% |
| Rhenman & Partners Asset Management ABas of 30 Jun 2025 | 450.00k | 0.68% |
| SEB Funds ABas of 30 Jan 2026 | 397.89k | 0.61% |
| Skandia Investment Management ABas of 28 Nov 2025 | 288.79k | 0.44% |
| Storebrand Asset Management ASas of 31 Jan 2026 | 136.04k | 0.21% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
